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Excessive iron in specific tissues (iron
loading) promotes infection, neoplasia, cardi-
omyopathy, arthropathy, and a profusion of
endocrine and possibly neurodegenerative disor-
ders (1-5). An array of behavioral, medical, and
immunologic methods are being developed to
decrease iron loading or its detrimental effects.
Routine screening for iron loading in populations
exposed to certain diseases can provide valuable
epidemiologic, diagnostic, prophylactic, and
therapeutic information.
Hazards of Iron Loading
Iron can contribute to disease development
in several ways. Excessive amounts of the metal
in specific tissues and cells can hinder the ability
of proteins, such as transferrin and ferritin, to
prevent accretion of free iron. Moreover, in
infectious diseases, inflammatory diseases, and
illnesses that involve ischemia and reperfusion,
iron causes reactions that produce superoxide
radicals (6). Nonprotein bound ferric ions are
reduced by superoxide, and the ferrous product
is reoxidized by peroxide to regenerate ferric ions
and yield hydroxyl radicals, which attack all
classes of biologic macromolecules. Hydroxyl
radicals can depolymerize polysaccharides,
cause DNA strand breaks, inactivate enzymes,
and initiate lipid peroxidation (6).
Iron can also increase disease risk by
functioning as a readily available essential
nutrient for invading microbial and neoplastic
cells. To survive and replicate in hosts, microbial
pathogens must acquire host iron. Highly virulent
strains possess exceptionally powerful mecha-
nisms for obtaining host iron from healthy hosts
(7). In persons whose tissues and cells contain
excessive iron, pathogens can much more readily
procure iron from molecules of transferrin that
are elevated in iron saturation. In such cases,
even microbial strains that are not ordinarily
dangerous can cause illness. Markedly invasive
neoplastic cell strains can glean host iron more
easily than less malignant strains or normal host
cells (3). Moreover, iron-loaded tissues are
especially susceptible to growth of malignant
cells (Table 1).
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Iron is an oxidant as well as a nutrient for invading microbial and neoplastic cells.
Excessive iron in specific tissues and cells (iron loading) promotes development of
infection, neoplasia, cardiomyopathy, arthropathy, and various endocrine and possibly
neurodegenerative disorders. To contain and detoxify the metal, hosts have evolved an
iron withholding defense system, but the system can be compromised by numerous
factors. An array of behavioral, medical, and immunologic methods are in place or in
development to strengthen iron withholding. Routine screening for iron loading could
provide valuable information in epidemiologic, diagnostic, prophylactic, and therapeutic
studies of emerging infectious diseases.
Table 1. Iron loading in specific tissues and increased
risk for disease
Tissue type Disease
Alveolar macrophages Pulmonary neoplasia and
  infection
Anterior pituitary Gonadal and growth
  dysfunction
Aorta; carotid and Atherosclerosis
  coronary arteries
Colorectal mucosa Adenoma, carcinoma
Heart Arrhythmia,
  cardiomyopathy
Infant intestine Botulism, salmonellosis,
  sudden death
Joints Arthropathy
Liver Viral hepatitis, cirrhosis,
  carcinoma
Macrophages Intracellular infections
Pancreas Acinar and beta cell
  necrosis, carcinoma
Plasma and lymph Extracellular infections
Skeletal system Osteoporosis
Skin Leprosy, melanoma
Soft tissue Sarcoma
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Table 2. Microbial genera with strains whose growth in body fluids, cells, tissues, and intact vertebrate hosts is
stimulated by excess iron (8)
Gram-positive and acid-
Fungi Protozoa fast bacteria Gram-negative bacteria
Candida Entamoeba Bacillus Acinetobacter Klebsiella
Cryptococcus Leishmania Clostridium Aeromonas Legionella
Histoplasma Naegleria Corynebacterium Alcaligenes Moraxella
Paracoccidioides Plasmodium Erysipelothrix Campylobacter Neisseria
Pneumocystis Toxoplasma Listeria Capnocytophaga Pasteurella
Pythium Trypanosoma Mycobacterium Chlamydia Proteus
Rhizopus Staphylococcus Ehrlichia Pseudomonas
Trichosporon Streptococcus Enterobacter Salmonella
Escherichia Shigella
How Microbes Acquire Iron: A
Determinant of Host Range and of Tissue
Localization
The number of infectious disease agents
whose virulence is enhanced by iron continues to
increase (Table 2). To obtain host iron, successful
pathogens use one or more of four strategies:
binding of ferrated siderophilins with extraction
of iron at the cell surface; erythrocyte lysis,
digestion of hemoglobin, and heme assimila-
tion; use of siderophores that withdraw iron
from transferrin; and procurement of host
intracellular iron.
Microbial strains that use siderophilin
binding often have a very narrow host range (7).
Bacterial receptors recognize siderophilins
generally from a single or closely related host
species. Strains of Haemophilus somnus, for
example, form receptors for bovine but not for
human transferrin; these bacteria are virulent
for cattle but not for humans (9). The human
pathogen,  Neisseria meningitidis, can bind
ferrated transferrins from humans and such
hominids as chimpanzees, gorillas, and orangu-
tans, but not from monkeys or nonprimate
mammals (10,11). Actinobacillus pleuropneumoniae
synthesizes a swine-specific transferrin receptor
and causes pneumonia only in hogs (12).
Each of the above three pathogens, as well as
other organisms that use siderophilin binding,
can often obtain iron from heme. Helicobacter
pylori, for instance, first obtains iron from
human ferrated lactoferrin in the gastric lumen.
Then, as it migrates into intercellular junctions
of epithelial cells in the gastric wall, its sole
source of iron is heme. This pathogen binds
neither bovine ferrated lactoferrin nor human,
bovine, or equine ferrated transferrin (13).
However, not every pathogen that uses
siderophilin binding has a narrow host range.
For example, Staphylococcus aureus can be
virulent for a variety of mammalian species.
Strains of this organism can bind human, rat,
and rabbit transferrins and, much less
efficiently, bovine, porcine, and avian transfer-
rins (14). Moreover, isolates of S. aureus also
may produce siderophores (15,16). These small
molecules can withdraw iron from transferrins
synthesized by a variety of host species. The
siderophore, staphyloferrin A, removes iron from
both human and porcine transferrin; thus, the
metal can be available to invading cells in
humans and in hogs. Erythrocyte lysis, digestion
of hemoglobin, and heme assimilation are
available to strains of S. aureus. Bacterial
hemolysins generally are active against erythro-
cytes from several, although not from all,
potential host species.
Virulent streptococci are examples of
bacteria that neither bind siderophilins nor
produce siderophores yet proficiently invade and
replicate in many tissues in diverse host species.
The cellulytic activities of these pathogens
enable them to access such intracellular sources
of host iron as hemoglobin, myoglobin, catalase,
and ferritin (17).
The remarkable versatility for host species
shown by Listeria monocytogenes illustrates the
adeptness of this organism in procuring iron.
Although mainly a saprophyte that lives in the
plant-soil environment, L. monocytogenes can be
acquired by humans and other mammals
through ingestion of undercooked tissue of other
mammals, birds, fish, and Crustacea, as well as
from raw vegetables. Unable to bind siderophilins
or form siderophores, L. monocytogenes obtains348 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Table 3. The iron withholding defense system (1,8)
Constitutive components
Siderophilins
Transferrin in plasma, lymph, cerebrospinal fluid
Lactoferrin in secretions of lachrymal and mammary glands and of respiratory,
   gastrointestinal, and  genital tracts
Ferritin within host cells
Processes induced at time of invasion
Suppression of assimilation of 80% of dietary irona
Suppression of iron efflux from macrophages that have digested effete erythrocytes to result in 70%
   reduction in plasma irona
Increased synthesis of ferritin to sequester withheld irona
Release of neutrophils from bone marrow into circulation and then into site of infectiona
Release of apolactoferrin from neutrophil granules followed by binding of iron in septic sites
Macrophage scavenging of ferrated lactoferrin in areas of sepsis and of tumor cell clusters
Hepatic release of haptoglobin and hemopexin (to bind extravasated hemoglobin and
   hemin, respectively)
Synthesis of nitric oxide (from L-arginine) by macrophages to disrupt iron metabolism of invadersb
Suppression of growth of microbial cells within macrophages via downshift of expression of
   transferrin receptors and enhanced synthesis of Nrampl (23) by the host cellsb
Induction in B lymphocytes of synthesis of immunoglobulins to iron-repressible cell surface proteins
   that bind either heme, ferrated siderophilins, or ferrated siderophores
aActivated by interleukin-1 or -6 or by tumor necrosis factor-a.
bActivated by interferon-g.
iron by using either exogenous siderophores of
other microorganisms or natural catechols, such
as dopamine and norepinephrine, in host tissues.
The pathogen expresses a cell surface ferric
reductase that recognizes the siderophoric
chelated iron site; the metal is then reduced and
assimilated (18). Furthermore, in contrast to
saprophytic strains, systemic pathogenic strains
of L. monocytogenes are hemolytic.
To grow within host cells, pathogens
apparently are not required to synthesize
siderophilin binding sites or form siderophores.
For instance, unlike the wild type, siderophore-
minus mutants of Salmonella Typhimurium
cannot grow in extracellular compartments of
the host. However, both the wild and mutant
strains replicate within host cells (19). Possible
sources of intracellular iron are heme, iron
released from transferrin at pH 5.5-6, and ferritin.
For at least two pathogens, Francisella
tularensis and Legionella pneumophila, the host
intracellular niche is obligatory. Like the mutant
strain of S. Typhimurium, these organisms are
unable to access iron in extracellular fluids and
tissues. Culturing these bacteria in laboratory
media requires markedly elevated concentra-
tions of iron (20,21).
In host intracellular niches, growth of
microbial pathogens is stimulated by elevation
and depressed by decrease of iron. Indeed, at
least one bacterial pathogen, Ehrlichia
chaffeensis, induces elevation of iron in its host
cells; intracellular inclusions of the organism
cause the host cell to upregulate expression of
the transferrin receptor mRNA (22).
Iron Withholding Defense System
Hosts use several mechanisms (Table 3) to
withhold iron from invading microbial and
neoplastic cells: stationing of potent iron binding
proteins at sites of impending microbial
invasion; lowering iron levels in body fluids,
diseased tissues, and invaded cells during
invasion; and synthesizing immunoglobulins to
the iron acquisition antigens of microbes.
High concentrations of iron not only benefit
invading cells, they may also mediate
antimicrobial activities of defense cells. In in
vitro studies, 150 µM iron augmented macrophage
killing of Brucella abortus (24) and, without
altering phagocytosis, 250 µM iron enhanced
anti-Candida activity of microglia (25). In the
latter system, the metal suppressed synthesis of
nitric oxide but not of tumor necrosis factor A. By
generating oxidant-sensitive mediators, iron
may focus influx of neutrophils to sites of
infection (26). Iron loading of staphylococci
increased their killing by peroxide, macrophages,349 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Table 4. Conditions that can compromise iron
withholding (1,3)
Excessive intake of iron through intestinal absorption
Behavioral and nutritional factors
Accidental ingestion of iron tablets
Adulteration of processed foods with
   inorganic iron or blood
Excessive consumption of red meats
   (heme iron)
Excessive intake of alcohol (HCl
   secretion enhanced)
Folic acid deficiency
Ingestion of ascorbic acid with
   inorganic iron
Use of iron cookware
Genetic and physiological factors
African siderosis
Asplenia (mechanism unknown)
Pancreatic deficiency of bicarbonate ions
Porphyria cutanea tarda
Regulatory defect in mucosal cells in
   hemochromatosis
Thalassemia, sicklemia, other
   hemoglobinopathies
Parenteral iron
Intramuscular and intravenous iron
   saccharate injections in excess
Multiple transfusions of whole blood or
   erythrocytes in excess
Inhaled iron
Exposure to amosite, crocidolite, or tremolite
   asbestos
Exposure to urban air particulates
Mining iron ore, welding, grinding steel
Painting with iron oxide powder
Tobacco smoking (1-2 µg iron inhaled per
   cigarette pack)
Release of body iron from compartments into plasma
Efflux of erythrocyte iron in hemolytic diseases
Efflux of hepatocyte iron in hepatitis
Deficit in iron withholding
Transferrin
Decreased synthesis
Congenital defect
Lack of dietary amino acids in
   kwashiorkor or in jejunoileal bypass
Decreased activity in acidosis
Lactoferrin
Neutropenia
Substitution of bovine milk or milk
  formula for human milk in nursling
  nutrition
Haptoglobin
Decreased synthesis in persons with
  haplotype 2-2 (28)
and neutrophil-derived cytoplasts but not by
neutrophils (27). Certain conditions can impair
iron withholding (Table 4); numerous studies
have presented evidence that risk for infection or
neoplasia is increased significantly in persons
with these conditions.
Detection of Iron Loading
Screening of large populations for iron
loading can be accomplished with inexpensive,
noninvasive methods. A useful indicator of iron
loading is marked elevation of serum ferritin
(sFt). However, sole reliance on this measure-
ment can be misleading because sFt increases
moderately during inflammatory episodes.
Accordingly, concurrent determination of the
percentage of iron saturation of serum transfer-
rin (%TS) provides useful information (29). In
iron loaded persons, hyperferritinemia generally
is accompanied by an elevation in %TS. In
contrast, in patients with an inflammatory
process, hyperferritinemia generally is accompa-
nied by a reduction in %TS.
Iron loading is associated also with moderate
depression of a third variable, serum transferrin
receptor (sTfR). The ratio of sTfR/sFt, apparently
independent of inflammation, is significantly
reduced in persons with high levels of iron (5).
Strengthening the Iron Withholding
Defense
A considerable array of behavioral, medical,
and immunologic methods are in place or in
development for strengthening iron withholding
(Table 5) (3). Additional precautions are
indicated for persons who are known to be (or
have a tendency to become) iron loaded. For
example, persons with elevated iron due to either
hemochromatosis or alcoholism are cautioned to
avoid eating raw oysters, which may contain
Vibrio vulnificus (30). Another pathogen that
likewise causes severe systemic infection in
hosts with elevated iron is Capnocytophaga
canimorsis. Accordingly, persons who have
hemochromatosis, alcoholism, or asplenia are
advised to receive prompt antibiotic therapy if
they are exposed to a dog bite (31).
De-ironing by phlebotomy is effective in
lowering risk for cardiovascular diseases (32,33)
and various neoplasms (34), as well as in therapy
for hepatitis C (35). Interfering with iron
metabolism by administering gallium can be
useful in suppressing growth of lymphoma and
bladder cancer cells (36). The antineoplastic
action of monoclonal antibodies against ferrated
transferrin receptors has been examined (37).350 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Table 5. Methods of strengthening the iron withholding defense system
Reduction of excessive intake of ingested iron
Decreased consumption of red meats (heme iron)
Avoidance of processed foods that have been adulterated with inorganic iron or with blood
Decreased consumption of alcohol and ascorbic acid
Elimination of iron supplements unless an iron deficiency has been correctly diagnosed
Reduction of excessive intake of parenteral iron
Inject iron saccharates only if unequivocally justified
Transfuse blood or erythrocytes only if unequivocally justified
Substitute erythropoietin (+ minimal amount of iron) for whole blood transfusions when possible
Reduction of excessive inhalation of iron
Eliminate use of tobacco
Use iron-free chrysotile in place of iron-loaded amosite, crocidolite, tremolite varieties of asbestos
Use mask to avoid inhalation of urban air particulates
Use mask and protective clothing when mining or cutting ferriferous substances
Reduction of iron burden by regular depletion of whole blood or erythrocytes
Avoidance of premature hysterectomy
Routine ingestion of aspirin
Regular donations of whole blood or erythrocytes
Vigorous exercise
Increased use of iron chelators
Use human milk (high in lactoferrin, low in iron) rather than milk formula (lacking in lactoferrin, high
   in iron) in nursling nutrition
Use tea (iron-binding tannins) and bran (iron-binding phytic acid)
Continue research and development (R&D) of potential iron chelator drugs (e.g., recombinant human
  lactoferrin; hydroxpyridones; pyridoxal isonicotinoyl hydrazones)
Initiation of prompt therapy of chronic infections and neoplastic diseases to forestall saturation of iron
  withholding defense system
Continued R&D of cytokines such as interferon g that induce cellular iron withholding
Continued R&D of passive and active methods of immunization against surface receptor  proteins used
   by microbial and neoplastic cells to obtain iron
Combinations of the iron chelator, deferoxamine,
with gallium or with antibodies against ferrated
transferrin receptors increase effectiveness
against tumor cells.
The natural iron scavenger, lactoferrin, has
been shown to remove free iron from synovial
fluid aspirated from joints of rheumatoid
arthritic patients (38). Recombinant human
lactoferrin, which is indistinguishable from
native breast milk lactoferrin with respect to its
iron binding properties, is now available (39) and
could become a very useful addition to our array
of de-ironing pharmaceutical products.
A recently discovered integral membrane
phosphoglycoprotein, Nrampl, is expressed
exclusively in macrophages and is localized to
phagolysosomes. The protein suppresses replica-
tion of intramacrophage microbial invaders
apparently by altering iron availability (23). A
second protein, Nramp2, is involved in
enhancement of intestinal iron absorption (40).
Future research might develop useful medical
procedures for modulation of the actions of
these  proteins.
Potential vaccines that incorporate iron
acquisition antigens of pathogens in the families
Neisseriaceae  and  Pasteurellaceae  are being
developed by several research groups. For
example, in Moraxella catarrhalis, the recombi-
nant transferrin binding protein B (TbpB) has
been shown to elicit bactericidal antibodies (41)
In N. meningitidis, antisera to TbpA and TbpB
were bactericidal for both homologous and
heterologous strains (42,43). Because the
antigenic proteins function at the cell surfaces of
the pathogens, the receptors are potentially ideal
vaccine candidates. For synthesis of the
receptors, the organisms must be cultured in
iron-restricted media.
Perspectives and Conclusions
There is growing awareness that transmis-
sible agents are involved in diseases not earlier
suspected of being infectious (44-46). A recent351 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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review contains a list of 34 degenerative,
inflammatory, and neoplastic diseases associ-
ated in various ways with specific infectious
agents (44). Other chronic inflammatory
diseases, such as sarcoidosis, inflammatory
bowel disease, rheumatoid arthritis, systemic
lupus erythematosus, Wegener granulomatosis,
diabetes mellitus, primary biliary cirrhosis,
tropical sprue, and Kawasaki disease may also
have infectious etiologies (45). Excessive iron is
correlated with synovial damage in rheumatoid
arthritis (47) and with impaired glucose
metabolism in diabetes (48). The association of
Chlamydia pneumoniae (49) and excessive iron
(5) with cardiovascular disease is well estab-
lished. Growth of this pathogen is strongly
suppressed by iron restriction (50).
Proving the role of infection in chronic
inflammatory diseases and cancer presents
challenges (46). The means by which pathogens
suppress, subvert, or evade host defenses to
establish chronic or latent infection have
received little attention. However, the associa-
tion and causal role of infectious agents in
chronic inflammatory diseases and cancer have
major implications for public health, treatment,
and prevention (44-46).
Iron loading is a risk factor in these illnesses,
as well as in classic infectious diseases. Because
the prevalence of iron loading in various
populations can be remarkably high, routine
screening of iron values in host populations could
provide valuable information in epidemiologic,
diagnostic, prophylactic, and therapeutic studies
of emerging infectious diseases.
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